Co-stimulatory members of the TNFR family: Keys to effective T-cell immunity?

Nature Reviews Immunology

Volumn 3, Issue 8, 2003, Pages 609-620

  Croft, Michael ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 1BB ANTIGEN; CD134 ANTIGEN; CD27 ANTIGEN; CD28 ANTIGEN; CD30 ANTIGEN; HERPES VIRUS ENTRY MEDIATOR ANTIGEN; IMMUNOGLOBULIN; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; CD137 ANTIGEN; DIFFERENTIATION ANTIGEN; HERPESVIRUS ENTRY MEDIATOR; LEUKOCYTE ANTIGEN; NERVE GROWTH FACTOR RECEPTOR; OX40IG; TNFRSF14 PROTEIN, HUMAN; TNFRSF14 PROTEIN, MOUSE; TNFRSF9 PROTEIN, HUMAN; TNFRSF9 PROTEIN, MOUSE; VIRUS RECEPTOR;

CELLULAR IMMUNITY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LIGAND BINDING; MEMORY CELL; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MOUSE;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD137; ANTIGENS, CD27; ANTIGENS, CD30; ANTIGENS, DIFFERENTIATION; HUMANS; LYMPHOCYTE ACTIVATION; MICE; RECEPTORS, NERVE GROWTH FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 14; RECEPTORS, VIRUS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 0141609073     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1148     Document Type: Review

References (130)

1. Bodmer, J. L., Schneider, P. & Tschopp, J. The molecular architecture of the TNF superfamily. Trends Biochem. Sci. 27, 19-26 (2002).
2. Locksley, R. M., Killeen, N. & Lenardo, M. J. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 104, 487-501 (2001).
3. Borst, J. et al. Alternative molecular form of human T cell-specific antigen CD27 expressed upon T cell activation. Eur. J. Immunol. 19, 357-364 (1989).
4. Morel, Y. et al. Reciprocal expression of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T cells: LIGHT down-regulates its own receptor. J. Immunol. 165, 4397-4404 (2000).
5. Gramaglia, I., Weinberg, A. D., Lemon, M. & Croft, M. Ox-40 ligand: a potent co-stimulatory molecule for sustaining primary CD4 T cell responses. J. Immunol. 161, 6510-6517 (1998).
6. Pollok, K. E., Kim, S. H. & Kwon, B. S. Regulation of 4-1BB expression by cell-cell interactions and the cytokines, interleukin-2 and interleukin-4. Eur. J. Immunol. 25, 488-494 (1995).
7. + T cells. J. Immunol. 151, 2380-2389 (1993).
8. de Jong, R. et al. Regulation of expression of CD27, a T cell-specific member of a novel family of membrane receptors. J. Immunol. 146, 2488-2494 (1991).
9. Gravestein, L. A. et al. Cloning and expression of murine CD27: comparison with 4-1BB, another lymphocyte-specific member of the nerve growth factor receptor family. Eur. J. Immunol. 23, 943-950 (1993).
10. Lens, S. M., Baars, P. A., Hooibrink, B., van Oers, M. H. & van Lier, R. A. Antigen-presenting cell-derived signals determine expression levels of CD70 on primed T cells. Immunol. 90, 38-45 (1997).
11. Mauri, D. N. et al. LIGHT, a new member of the TNF superfamily, and lymphotoxin-α are ligands for herpesvirus entry mediator. Immunity 8, 21-30 (1998).
12. Wiley, S. R., Goodwin, R. G. & Smith, C. A. Reverse signaling via CD30 ligand. J. Immunol. 157, 3635-3639 (1996).
13. Baum, P. R. et al. Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34. EMBO J. 13, 3992-4001 (1994).
14. Gilfillan, M. C., Noel, P. J., Podack, E. R., Reiner, S. L. & Thompson, C. B. Expression of the co-stimulatory receptor CD30 is regulated by both CD28 and cytokines. J. Immunol. 160, 2180-2187 (1998).
15. Walker, L. S. et al. Compromised OX40 function in CD28-deficient mice is linked with failure to develop CXC chemokine receptor 5-positive CD4 cells and germinal centers. J. Exp. Med. 190, 1115-1122 (1999).
16. L and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 15, 445-455 (2001). Using knockout T cells, this paper defines the sequential action of OX40 after CD28, and shows that OX40 controls T-cell survival through regulating antiapoptotic BCL2-family members.
17. H-independent priming of CTL in the presence of an intact CD28 co-stimulatory pathway. J. Immunol. 168, 3755-3762 (2002).
18. Lens, S. M. et al. Phenotype and function of human B cells expressing CD70 (CD27 ligand). Eur. J. Immunol. 26, 2964-2971 (1996).
19. Pollok, K. E. et al. 4-1BB T-cell antigen binds to mature B cells and macrophages, and co-stimulates anti-μ-primed splenic B cells. Eur. J. Immunol. 24, 367-374 (1994).
20. Ohshima, Y. et al. Expression and function of OX40 ligand on human dendritic cells. J. Immunol. 159, 3838-3848 (1997).
21. Shanebeck, K. D. et al. Regulation of murine B cell growth and differentiation by CD30 ligand. Eur. J. Immunol. 25, 2147-2153 (1995).
22. Hintzen, R. Q. et al. Characterization of the human CD27 ligand, a novel member of the TNF gene family. J. Immunol. 152, 1762-1773 (1994).
23. Tamada, K. et al. LIGHT, a TNF-like molecule, co-stimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J. Immunol. 164, 4105-4110 (2000).
24. Oshima, H. et al. Characterization of murine CD70 by molecular cloning and mAb. Int. Immunol. 10, 517-526 (1998).
25. Futagawa, T. et al. Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int. Immunol. 14, 275-286 (2002).
26. Kwon, B. S. et al. A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J. Biol. Chem. 272, 14272-14276 (1997).
27. Harrop, J. A. et al. Antibodies to TR2 (herpesvirus entry mediator), a new member of the TNF receptor superfamily, block T cell proliferation, expression of activation markers, and production of cytokines. J. Immunol. 161, 1786-1794 (1998).
28. Tamada, K. et al. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nature Med. 6, 283-289 (2000). The authors show that LIGHT has potent co-stimulatory activity, with an important role in graft-versus-host disease and can promote antitumour responses.
29. Ye, Q. et al. Modulation of LIGHT-HVEM co-stimulation prolongs cardiac allograft survival. J. Exp. Med. 195, 795-800 (2002).
30. Scheu, S. et al. Targeted disruption of LIGHT causes defects in co-stimulatory T cell activation and reveals cooperation with lymphotoxin-β in mesenteric lymph node genesis. J. Exp. Med. 195, 1613-1624 (2002).
31. Shaikh, R. B. et al. Constitutive expression of LIGHT on T cells leads to lymphocyte activation, inflammation, and tissue destruction. J. Immunol. 167, 6330-6337 (2001).
32. Wang, J. et al. The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT. J. Clin. Invest. 108, 1771-1780 (2001).
33. + T cell function in mice lacking the TNF superfamily member LIGHT. J. Immunol. 168, 4832-4835 (2002).
34. Wan, X. et al. A TNF family member LIGHT transduces co-stimulatory signals into human T cells. J. Immunol. 169, 6813-6821 (2002).
35. Agematsu, K. et al. Role of CD27 in T cell immune response. Analysis by recombinant soluble CD27. J. Immunol. 153, 1421-1429 (1994).
36. Hintzen, R. Q. et al. Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation. J. Immunol. 154, 2612-2623 (1995).
37. Hendriks, J. et al. CD27 is required for generation and long-term maintenance of T cell immunity. Nature Immunol. 1, 433-440 (2000). This is the first description of CD27-deficient mice and shows that CD27 is essential for primary and secondary influenza-specific T-cell responses.
38. Arens, R. et al. Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFNγ-mediated B cell depletion. Immunity 15, 801-812 (2001).
39. Couderc, B. et al. Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) co-stimulatory molecules in tumor cells. Cancer Gene Ther. 5, 163-175 (1998).
40. Lorenz, M. G., Kantor, J. A., Schlom, J. & Hodge, J. W. Anti-tumor immunity elicited by a recombinant vaccinia virus expressing CD70 (CD27L). Hum. Gene Ther. 10, 1095-1103 (1999).
41. Chen, A. I. et al. Ox40-ligand has a critical co-stimulatory role in dendritic cell-T cell interactions. Immunity 11, 689-698 (1999).
42. H cell proliferation but are competent in generating B cell and CTL responses after virus infection. Immunity 11, 699-708 (1999).
43. Murata, K. et al. Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand. J. Exp. Med. 191, 365-374 (2000).
44. + T cells.
45. DeBenedette, M. A. et al. Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus. J. Immunol. 163, 4833-4841 (1999).
46. Tan, J. T., Whitmire, J. K., Ahmed, R., Pearson, T. C. & Larsen, C. P. 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses. J. Immunol. 163, 4859-4868 (1999).
47. + T-cell responses to viruses and virus peptides.
48. Cooper, D., Bansal-Pakala, P. & Croft, M. 41BB(CD137) controls the clonal expansion and survival of CD8 T cells in vivo but does not contribute to the development of cytotoxicity. Eur. J. Immunol. 32, 521-529 (2002).
49. Brocker, T. et al. CD4 T cell traffic control: in vivo evidence that ligation of OX40 on CD4 T cells by OX40-ligand expressed on dendritic cells leads to the accumulation of CD4 T cells in B follicles. Eur. J. Immunol. 29, 1610-1616 (1999).
50. Murata, K. et al. Constitutive OX40/OX40 ligand interaction induces autoimmune-like diseases. J. Immunol. 169, 4628-4636 (2002).
51. Bansal-Pakala, P., Gebre-Hiwot Jember, A. & Croft, M. Signaling through OX40 (CD134) breaks peripheral T-cell tolerance. Nature Med. 7, 907-912 (2001). The authors report that signalling through OX40 can prevent and reverse T-cell tolerance that is induced by encounter with soluble antigen in the absence of adjuvant.
52. Maxwell, J., Weinberg, A. D., Prell, R. A. & Vella, A. T. Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. J. Immunol. 164, 107-112 (2000).
53. Weatherill, A. R., Maxwell, J. R., Takahashi, C., Weinberg, A D. & Vella, A. T. OX40 ligation enhances cell cycle turnover of Ag-activated CD4 T cells in vivo. Cell. Immunol. 209, 63-75 (2001).
54. De Smedt, T. et al. OX40 co-stimulation enhances the development of T cell responses induced by dendritic cells in vivo. J. Immunol. 168, 661-670 (2002).
55. Melero, I. et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nature Med. 3, 682-685 (1997). The first to show that agonist reagents to 4-1BB can provide protection against tumours by augmenting the activity of cytotoxic T lymphocytes (CTLs).
56. Melero, I. et al. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 cc-stimulatory pathway. Eur. J. Immunol. 28, 1116-1121 (1998).
57. Takahashi, C., Mittler, R. S. & Vella, A. T. 4-1BB is a bona fide CD8 T cell survival signal. J. Immunol. 162, 5037-5040 (1999).
58. Guinn, B. A., DeBenedette, M. A., Watts, T. H. & Berinstein, N. L. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J. Immunol. 162, 5003-5010 (1999).
59. + T cell responses. Nature Immunol 3, 536-541 (2002).
60. Takahashi, C., Mittler, R. S. & Vella, A. T. Differential clonal expansion of CD4 and CD8 T cells in response to 4-1BB ligation: contribution of 4-1BB during inflammatory responses. Immunol. Lett. 76, 183-191 (2001).
61. Bansal-Pakala, P. & Croft, M. Defective T cell priming associated with aging can be rescued by signaling through 4-1BB (CD137). J. Immunol. 169, 5005-5009 (2002).
62. Bertram, E. M., Lau, P. & Watts, T. H. Temporal segregation of 4-1BB versus CD28-mediated co-stimulation: 4-1BB ligand influences T cell numbers late in the primary response and regulates the size of the T cell memory response following influenza infection. J. Immunol. 168, 3777-3785 (2002). This paper establishes the sequential action of 4-1BB late in the T-cell response after CD28.
63. Del Prete, G. et al. CD30-mediated signaling promotes the development of human T helper type 2-like T cells. J. Exp. Med. 182, 1655-1661 (1995).
64. Bowen, M. A., Lee, R. K., Miragliotta, G., Nam, S. Y. & Podack, E. R. Structure and expression of murine CD30 and its role in cytokine production J. Immunol. 156, 442-449 (1996).
65. + T cells by IL-4 and IFN-γ. J. Immunol. 158, 2090-2098 (1997).
66. Amakawa, R. et al. Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice. Cell 84, 551-562 (1996).
67. DeYoung, A. L., Duramad, O. & Winoto, A. The TNF receptor family member CD30 is not essential for negative selection. J. Immunol. 165, 6170-6173 (2000).
68. Saraiva, M., Smith, P., Fallon, P. G. & Alcami, A. Inhibition of type 1 cytokine-mediated inflammation by a soluble CD30 homologue encoded by ectromelia (mousepox) virus. J. Exp. Med. 196, 829-839 (2002). This paper shows that poxvirus produces a homologue of CD30 that can inhibit inflammation controlled by type 1 cytokines.
69. Podack, E. R., Strbo, N., Sotosec, V. & Muta, H. CD30-governor of memory T cells? Ann. NY Acad. Sci. 975, 101-113 (2002).
70. Akiba, H. et al. CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-κB and stress-activated protein kinase/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-κB-inducing kinase. J. Biol. Chem. 273, 13353-13358 (1998).
71. Aizawa, S. et al. Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NF-κB activation. J. Biol. Chem. 272, 2042-2045 (1997).
72. Ansieau, S. et al. Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor-κB activation. Proc. Natl Acad. Sci. USA 93, 14053-14058 (1996).
73. Arch, R. H. & Thompson, C. B. 4-1BB and OX40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor-κB. Mol. Cell. Biol. 18, 558-65 (1998).
74. Duckett, C. S., Gedrich, R. W., Gilfillan, M. C. & Thompson, C. B. Induction of nuclear factor-κB by the CD30 receptor is mediated by TRAF1 and TRAF2. Mol. Cell. Biol. 17, 1535-1542 (1997).
75. Hsu, H. et al. ATAR, a novel tumor necrosis factor receptor family member signals through TRAF2 and TRAF5. J. Biol. Chem. 272, 13471-13474 (1997).
76. Kawamata, S. Hori, T., Imura, A., Takaori-Kondo, A. & Uchiyama, T. Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2- and TRAF5-mediated NF-κB activation. J. Biol. Chem. 273, 5808-5814 (1998).
77. Gravestein, L. A. et al. The TNF receptor family member CD27 signals to Jun N-terminal kinase via Traf-2. Eur. J. Immunol. 28, 2208-2216 (1998).
78. Jang, I. K., Lee, Z. H., Kim, Y. J., Kim, S. H. & Kwon, B. S. Human 4-1BB (CD137) signals are mediated by TRAF2 and activate nuclear factor-κB. Biochem. Biophys. Res. Commun. 242, 613-620 (1998).
79. Saoulli, K. et al. CD28-independent, TRAF2-dependent co-stimulation of resting T cells by 4-1BB ligand. J. Exp. Med. 187, 1849-1862 (1998).
80. Yamamoto, H., Kishimoto, T. & Minamoto, S. NF-κB activation in CD27 signaling: involvement of TNF receptor-associated factors in its signaling and identification of functional region of CD27. J. Immunol. 161, 4753-4759 (1998).
81. Marsters, S. A. et al. Herpes virus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-κB and AP-1. J. Biol. Chem. 272, 14029-14032 (1997).
82. Cannons, J. L., Hoeflich, K. P., Woodgett, J. R. & Watts, T. H. Role of the stress kinase pathway in signaling via the T cell co-stimulatory receptor 4-1BB. J. Immunol. 163, 2990-2998 (1999).
83. L and Bfl-1. J. Immunol. 169, 4882-4888 (2002).
84. + T cells. Int. Immunol. 14, 1155-1167 (2002).
85. Brennan, P. et al. Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F. Immunity 7, 679-689 (1997).
86. Harhaj, E. W. & Sun, S. C. IκB kinases serve as a target of CD28 signaling. J. Biol. Chem. 273, 25185-25190 (1998).
87. Su, B. et al. JNK is involved in signal integration during co-stimulation of T lymphocytes. Cell 77, 727-736 (1994).
88. Prasad, K. V. et al. T-cell antigen CD28 interacts with the lipid kinase phosphatidylinositol 3-kinase by a cytoplasmic Tyr(P)-Met-Xaa-Met motif. Proc. Natl Acad. Sci. USA 91, 2834-2838 (1994).
89. H2 cytokines. Nature Immunol. 2, 37-44 (2001).
90. L. Immunity 3, 87-98 (1995).
91. H2 cytokine secretion in vivo. J. Exp. Med. 197, 875-883 (2003).
92. - accessory cells co-stimulate primed CD4 T Cells through OX40 and CD30 at sites where T cells collaborate with B cells. Immunity 18, 643-654 (2003). Together with reference 91, this paper defines populations of antigen-presenting cells (APCs), other than dendritic cells, that can deliver late-acting survival signals from tumour-necrosis factor (TNF)-family ligands.
93. Blazar, B. R. et al. Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients. J. Immunol. 166, 3174-3183 (2001).
94. Gramaglia, I., Cooper, D., Miner, K. T., Kwon, B. S. & Croft, M. Co-stimulation of antigen-specific CD4 T cells by 4-1BB ligand. Eur. J. Immunol. 30, 392-402 (2000).
95. Cannons, J. L. et al. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J. Immunol. 167, 1313-1324 (2001)
96. Akiba, H. et al. Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis. J. Exp. Med. 191, 375-380 (2000).
97. Jember A. G., Zuberi, R., Liu, F. T. & Croft, M. Development of allergic inflammation in a murine model of asthma is dependent on the co-stimulatory receptor OX40. J. Exp. Med. 193, 387-392 (2001).
98. + lymphocytes contains functionally differentiated T lymphocytes that develop by persistent antigenic stimulation in vivo. Eur. J. Immunol. 22, 993-999 (1992).
99. Salek-Ardakani, S. et al. OX40 (CD134) controls memory T helper 2 cells that drive lung inflammation. J. Exp. Med. 198, 1-12 (2003). This paper shows that OX40 directly controls the secondary response of memory T cells and, similar to its action in the primary response, regulates the frequency of effector cells that are generated.
100. - T cells. Blood 100, 3253-3260 (2002).
101. Cannons, J. L., Bertram, E. M. & Watts, T. H. Cutting edge: profound defect in T cell responses in TNF receptor-associated factor 2 dominant negative mice. J. Immunol. 169, 2828-2831 (2002).
102. Yoshioka, T. et al. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis. Eur. J. Immunol. 30, 2815-2823 (2000).
103. H1 cell responses. Eur. J. Immunol. 28, 881-890 (1998).
104. - T cells by 4-1BB ligand. Eur. J. Immunol. 33, 446-454 (2003).
105. Maus, M. V. et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB, Nature Biotechnol. 20, 143-148 (2002).
106. Tsukada, N. et al. Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation. Blood 95, 2434-2439 (2000).
107. Blazar, B. R. et al. Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogenic bone marrow transplant (BMT) recipients. Blood 101, 3741-3748 (2003).
108. Macian, F. et al. Transcriptional mechanisms underlying lymphocyte tolerance. Cell 109, 719-731 (2002).
109. Sun, Y. et al. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J. Immunol. 168, 1457-1465 (2002).
110. Sun, Y. et al. Co-stimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nature Med. 8, 1405-1413 (2002). Together with reference 109, the authors show that an agonist reagent to 4-1BB can suppress rather than enhance an immune response that is ongoing. This indicates that the nature of any co-stimulation therapy might need to be varied depending on the disease and the stage at which it is targeted.
111. Zhu, G. et al. Progressive depletion of peripheral B lymphocytes in 4-1 BB (CD137) ligand/I-Eα-transgenic mice. J. Immunol. 167, 2671-2676 (2001).
112. Nakajima, A. et al. Involvement of CD70-CD27 interactions in the induction of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 109, 188-196 (2000).
113. Weinberg, A. D. et al. Selective depletion of myelin-reactive T cells with the anti-OX40 antibody ameliorates autoimmune encephalomyelitis. Nature Med. 2, 183-189 (1996). The first to report that targeting OX40 can be therapeutically beneficial in a model of disease.
114. Weinberg, A. D., Wegmann, K. W., Funatake, C. & Whitham, R. H. Blocking OX40-OX40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J. Immunol. 162, 1818-1826 (1999).
115. Nohara, C. et al. Amelioration of experimental autoimmune encephalomyelitis with anti-OX40 ligand monoclonal antibody: a critical role for OX40 ligand in migration, but not development, of pathogenic T cells. J. Immunol. 166, 2108-2115 (2001).
116. Ndhlovu, L. C., Ishii, N., Murata, K., Sato, T. & Sugamura, K. Critical involvement of OX40 ligand signals in the T cell priming events during experimental autoimmune encephalomyelitis. J. Immunol. 167, 2991-2999 (2001).
117. H2 responses in allergic inflammation. Eur. J. Immunol. 32, 2874-2880 (2002).
118. Higgins, L. M. et al. Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein. J. Immunol. 162, 486-493 (1999).
119. Malmstrom, V et al. CD134L expression on dendritic cells in the mesenteric lymph nodes drives colitis in T cell-restored SCID mice. J. Immunol. 166, 6972-6981 (2001).
120. H2 response to the gastrointestinal nematode parasite Heligmosomoides polygyrus. J. Immunol. 170, 384-393 (2003).
121. Zhal, Y. et al. LIGHT, a novel ligand for lymphotoxin β receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J. Clin. Invest. 102, 1142-1151 (1998).
122. Nieland, J. D., Graus, Y. F., Dortmans, Y. E., Kremers, B. L. & Kruisbeek, A. M. CD40 and CD70 co-stimulate a potent in vivo antitumor T cell response. J. Immunother. 21, 225-236 (1998).
123. Weinberg, A. D. et al. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J. Immunol. 164, 2160-2169 (2000).
124. Kjaergaard, J. et al. Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res. 60, 5514-5521 (2000).
125. Pan, P., Zang, Y., Weber, K., Meseck, M. & Chen, S. OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases. Mol. Ther. 6, 528-536 (2002).
126. Gri, G., Gallo, E., Di Carlo, E., Musiani, P & Colombo, M. P. OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-APC signaling to boost the host T cell antitumor response. J. Immunol. 170, 99-106 (2003).
127. Strome, S. E. et al. Enhanced therapeutic potential of adoptive immunotherapy by in vitro CD28/4-1BB co-stimulation of tumor-reactive T cells against a poorly immunogenic, major histocompatibility complex class I-negative A9p melanoma. J. Immunother. 23, 430-437 (2000).
128. + murine squamous cell carcinoma and the requirements of co-stimulatory molecules on tumour and host cells. Immunol. 101, 541-547 (2000).
129. Wilcox, R. A. et al. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J. Clin. Invest. 109, 651-659 (2002).
130. Ye, Z. et al. Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB. Nature Med. 8, 343-348 (2002).